{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:50:59Z","timestamp":1781790659174,"version":"3.54.5"},"reference-count":12,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Hum Lact"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Eslicarbazepine acetate is an anti-seizure medication. Only very few data are available regarding its use during lactation, and women treated with eslicarbazepine acetate for drug resistant epilepsy would sometimes give up with breastfeeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Issue:<\/jats:title>\n                    <jats:p>We report on the successful outcome of two successive infants breastfed by a mother treated with eslicarbazepine acetate for pharmacoresistant epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management:<\/jats:title>\n                    <jats:p>To evaluate the exposure to eslicarbazepine acetate through maternal milk, the infants\u2019 serum levels have been measured. The infant serum concentrations of eslicarbazepine were 1.8\u2009mg\/L at 14\u2009days of life (i.e., 9.1% of the maternal serum concentration) for the first child and 1.5\u2009mg\/L at 18\u2009days of life for the second child. No adverse drug reactions were reported in either infant after 13\u2009months of breastfeeding for each infant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Although no previous data on the use of eslicarbazepine acetate during lactation are available, limited but reassuring data have been reported with oxcarbazepine, of which eslicarbazepine is a major metabolite. Given the well-known benefits of breastfeeding, and according to the above reassuring data, breastfeeding under clinical supervision could be considered for healthy full-term infants of mothers on eslicarbazepine acetate monotherapy. However, parents should be warned that data concerning the safety of eslicarbazepine during breastfeeding are scarce, and long-term neurodevelopment outcomes in breastfed children are unknown. Additionally, the infants\u2019 serum levels should be measured in case of an unexplained adverse reaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08903344261426739","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:17:54Z","timestamp":1774531074000},"page":"479-484","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Eslicarbazepine Use During Breastfeeding: A Case Report"],"prefix":"10.1177","volume":"42","author":[{"given":"Thais","family":"Reversat-Brulant","sequence":"first","affiliation":[{"name":"Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Moschetti","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Atzenhoffer","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Pizzoglio-Billaudaz","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Bertin","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Vial","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5236-9083","authenticated-orcid":false,"given":"Marine","family":"Auffret","sequence":"additional","affiliation":[{"name":"Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, France"},{"name":"UMR 5558, Laboratoire de Biom\u00e9trie et Biologie \u00c9volutive, Universit\u00e9 Lyon 1, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Beken B. Can C. \u00d6rencik A. Can N. Yaz\u0131c\u0131o\u011flu M. (2017). Oxcarbazepine-induced Stevens-Johnson syndrome: A pediatric case report. Oxford Medical Case Reports 6 omx028. https:\/\/doi.org\/10.1093\/omcr\/omx028","DOI":"10.1093\/omcr\/omx028"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Birnbaum A. K. Meador K. J. Karanam A. Brown C. May R. C. Gerard E. E. Gedzelman E. R. Penovich P. E. Kalayjian L. A. Cavitt J. Pack A. M. Miller J. W. Stowe Z. N. Pennell P. B. & MONEAD Investigator Group. (2020). Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurology 77(4) 441\u2013450. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4443.","DOI":"10.1001\/jamaneurol.2019.4443"},{"key":"e_1_3_3_4_1","unstructured":"British National Formulary for Children. (2025). Eslicarbazepine. Medicines Complete. https:\/\/www.medicinescomplete.com\/#\/content\/bnfc\/_655011683"},{"key":"e_1_3_3_5_1","unstructured":"Drugbank. (2025). Eslicarbazepine acetate. DRUGBANK. https:\/\/go.drugbank.com\/drugs\/DB09119"},{"key":"e_1_3_3_6_1","unstructured":"Drugs@FDA: FDA-Approved Drugs. (2025). TRILEPTAL. U.S. Food & Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021014s036lbl.pdf"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Galiana G. L. Gauthier A. C. Mattson R. H. (2017). Eslicarbazepine acetate: A new improvement on a classic drug family for the treatment of partial-onset seizures. Drugs in R&D 17(3) 329\u2013339. https:\/\/doi.org\/10.1007\/s40268-017-0197-5.","DOI":"10.1007\/s40268-017-0197-5"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Gentile S. (2003). Oxcarbazepine in pregnancy and lactation. Clinical Drug Investigation 23(10) 687. https:\/\/doi.org\/10.2165\/00044011-200323100-00008.","DOI":"10.2165\/00044011-200323100-00008"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207812"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Lutz U. C. Wiatr G. Gaertner H. J. Bartels M. (2007). Oxcarbazepine treatment during breast-feeding: A case report. Journal of Clinical Psychopharmacology 27(6) 730\u2013732. https:\/\/doi.org\/10.1097\/JCP.0b013e31815a5819.","DOI":"10.1097\/JCP.0b013e31815a5819"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2005.05.011"},{"key":"e_1_3_3_12_1","volume-title":"Pharmacokinetics of oxcarbazepin in neonatal period and during lactation","author":"\u00d6hman I.","year":"2009","unstructured":"\u00d6hman I., Tomson T. (2009, September 21\u201325). Pharmacokinetics of oxcarbazepin in neonatal period and during lactation [Conference presentation abstract]. Eighth European Congress on Epileptology, Berlin, Germany."},{"key":"e_1_3_3_13_1","unstructured":"Sant\u00e9 Publique France. (2024). Epifane Study 2021. Infant feeding during their first year of life. https:\/\/www.santepubliquefrance.fr\/determinants-de-sante\/nutrition-et-activite-physique\/documents\/enquetes-etudes\/alimentation-des-nourrissons-pendant-leur-premiere-annee-de-vie.-resultats-de-l-etude-epifane-2021"}],"container-title":["Journal of Human Lactation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08903344261426739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08903344261426739","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08903344261426739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:52:27Z","timestamp":1781787147000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08903344261426739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/08903344261426739"],"URL":"https:\/\/doi.org\/10.1177\/08903344261426739","relation":{},"ISSN":["0890-3344","1552-5732"],"issn-type":[{"value":"0890-3344","type":"print"},{"value":"1552-5732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}